24 December 2025
DXS INTERNATIONAL PLC (AQSE: DXSP)
Update on Cyber Security Incident
The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, would like to provide an update on the security incident that affected its office servers, which was reported via RNS on 18 December.
The incident has been contained, and DXS remains vigilant by implementing additional monitoring and security measures.
The Directors of DXS International plc accept responsibility for this announcement.
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended (“MAR”). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Contacts :
| David Immelman
DXS International plc www.dxs-systems.com
|
01252 719800 |
| AQSE Corporate Broker and Corporate Advisor
Hybridan LLP Claire Louise Noyce |
020 3764 2341 |
Notes to Editors
About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.
Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed…
CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this…
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…
The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment…
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…
Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.…